#Ireland #Dublin #Mallinckrodt #Cencora #Leslie Donato

Mallinckrodt Enhances Board with New Appointment

On August 4, 2025, Mallinckrodt plc announced the appointment of Leslie Donato to its Board of Directors. This strategic move brings the board's total membership to nine and marks an important milestone as the company continues its evolution following the merger with Endo, Inc.

Leslie Donato is an established figure in the healthcare sector, renowned for her extensive expertise in strategy, corporate development, and product commercialization. Before joining Mallinckrodt, she held the position of Executive Vice President and Chief Strategy Officer at Cencora, Inc., where she successfully led transformative initiatives, committing over $10 billion for mergers and acquisitions and significantly boosting the company's market value.

Mallinckrodt's recent merger with Endo represents a significant turning point for the organization, positioning it as a leader in diversified therapeutics. The company aims to deliver effective solutions tailored to meet specialty healthcare demands, with a focus on addressing unmet patient needs in autoimmune and rare diseases.

Board Chair Paul Efron expressed confidence in Donato's appointment, stating, “Her substantial experience will greatly enrich our discussions and decision-making process.” This statement highlights the board’s commitment to driving forward the strategic agenda as they navigate new opportunities.

Leslie Donato brings more than three decades of experience to her new role. Prior to her impactful tenure at Cencora, she spent a decade at Bayer Healthcare Pharmaceuticals, where she advanced through various leadership positions, eventually overseeing strategic initiatives across different business segments. Her experience at McKinsey & Company further solidifies her career, where she played a pivotal role in enhancing performance for various pharmaceutical organizations.

Expressing her enthusiasm for the new role, Donato stated, “I'm privileged to help shape Mallinckrodt's new future. Our teams are now positioned for greater success under one unified company.” Her vision reflects a deep commitment to the revitalization of the newly merged company.

Adding to her credentials, Donato serves on the boards of Virtua Health System and COPILOT, institutions focused on improving patient access and healthcare solutions, further evidencing her dedication to the healthcare sector. Donato holds a Bachelor’s Degree in Economics and Public Policy from Swarthmore College and an MBA in Finance and Healthcare Management from The Wharton School of the University of Pennsylvania.

As Mallinckrodt moves forward, it aims to solidify its position as a leading provider of life-enhancing therapeutics while expanding into generic drugs and sterile injectables. With a solid leadership team bolstered by Donato's appointment, the company looks forward to an exciting future in addressing the needs of patients worldwide. This strategic overhaul represents not just an internal restructuring but a clear signal of Mallinckrodt’s commitment to innovation and efficacy in the healthcare space.

For more information on Mallinckrodt and its offerings, please visit Mallinckrodt's website.